相关实验视频

Updated: Jun 12, 2025

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

基于抗氧化质的半孔聚多巴胺的低血压纳米眼液,用于改善青光眼的治疗

Yate Huang¹, Xiaoxu Ding¹, Li Zhu¹

¹State Key Laboratory of Ophthalmology, Optometry and Vision Science, School of Ophthalmology & Optometry, Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang 325027, China.

Colloids and surfaces. B, Biointerfaces

|September 24, 2024

概括

装有布里莫尼丁的新型半孔多多巴胺纳米颗粒 (MPDA NPs) 通过增强药物输送和保护眼睛表面,改善了对玻璃眼的治疗. 这种新型纳米药物配方有效降低眼内压力 (IOP) 并减少氧化应激.

科学领域:

眼科医生眼科眼科
纳米技术纳米技术
材料科学材料科学材料科学

背景情况:

由于生物可用性差以及眼睛表面的副作用,传统的玻璃眼滴的疗效有限.
迫切需要先进的配方来改善角膜透,并提供眼睛表面保护.

研究的目的:

开发和评估抗氧化介质多多巴胺纳米颗粒 (MPDA NPs) 作为新型Brimonidine纳米载体.
评估布里莫尼丁装载MPDANP的增强的眼内压力 (IOP) 降低能力和眼睛表面保护作用.

主要方法:

使用模板移除方法合成MPDANP,并加载布里莫尼丁.
进行了PEGylation以获得近乎中性的表面电荷,以改善眼内输送.
该纳米配方的有效性在小鼠模型中进行了IOP降低和在小鼠模型中进行了对氧化应激的眼睛表面保护的测试.

主要成果:

与自由布里莫尼丁相比,基化,布里莫尼丁载入的MPDANP (MPDA-PEG@Brim) 显示出增强的角膜透率和水性幽默中的更高的布里莫尼丁度.
在高血压和正常血压的老鼠眼中观察到较高的内压降低.
在干眼模型中,MPDA-PEG NP有效地清除了自由基,减少了氧化应激,并减轻了眼睛表面损伤,并证实了体外和体内生物安全性.

结论:

MPDA-PEG@Brim纳米扩散代表了一种有希望的下一代低血压配方,用于治疗青光眼.
开发的纳米药物提供了扩展的眼睛表面保护和改善的治疗结果.
这项研究强调了抗氧化纳米颗粒在推进眼科药物输送系统方面的潜力.

关键词:

眼光障碍症是什么眼光障碍症是什么半孔性聚多巴胺胺 (Mesoporous polydopamine) 是一种中等的多巴胺.眼部药物输送是通过眼部药物输送的.有反应性氧物种的反应性氧物种.

更多相关视频

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Antihypertensive Drugs: Vasodilators

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...